| | L.E.K.’s Looking Ahead 2022 series of Executive Insights looks at how accelerated innovation has brought both unprecedented achievement and enduring challenges for companies throughout the healthcare ecosystem. Click to read more. |
|---|
'Leaner and simpler': Novartis details plans to cut 8,000 jobs worldwide 'Welcome to scrutiny': BIO chair mounts defense against more rigorous accelerated approval process Conflicting state laws and 'unpredictable' enforcement await providers in post-Roe America Cue Health to lay off 170 workers due to 'economic challenges,' COVID test funding cuts Mystery solved: Roivant is Pfizer's TYK2 partner—and is cutting other programs to fund late-phase trials Supreme Court won't take up lawsuit over PBM liability under ERISA Sanofi racks up 2 approvals in Europe for enzyme replacement therapies for rare diseases Schrödinger to launch first human trial of its computer-designed blood cancer drug Astellas pays Sutro $90M to hit cancer with one-two punch from new ADC modality Trial failure for Jazz’s cannabis-derived drug blunts goal to expand its use to US Bayer launches digital AI marketplace for analyzing CT, MRI scans CMS rolls out new payment model on improving cancer treatments Clinical trial data surge driving demand for management tech, Medidata says Featured Story | By Eric Sagonowsky For months, Novartis has hinted at layoffs coming for some of its global staff. Now, the news has come down from HQ. read more |
| |
|---|
|
Top Stories By Max Bayer As regulators and elected officials consider reforming the accelerated approval process, BIO chairman Paul Hastings is mounting a vigorous defense against proposals he says could threaten innovation. read more By Dave Muoio Single- and multistate provider organizations alike may find it difficult to keep their women's health services within the bounds of the law, attorneys say. read more By Andrea Park After rocketing to medtech stardom amid the COVID-19 pandemic, Cue Health seems to be drifting back down to Earth. read more By Nick Paul Taylor Pfizer has revealed the new home of its TYK2 inhibitors. Months after disclosing a pact with a mystery startup, the Big Pharma has taken the wrapping off a deal with Priovant Therapeutics, a new Roivant unit that will seek to bring brepocitinib to market in dermatomyositis and lupus. read more By Robert King The Supreme Court declined to take up a lawsuit challenging whether PBMs have a fiduciary duty under ERISA to keep drug prices low. read more By Kevin Dunleavy On Tuesday morning, Sanofi revealed two approvals from the European Commission—both for enzyme replacement treatments for rare diseases—that speak to CEO Paul Hudson’s mission to "play to win." read more By Conor Hale After working with biotechs and Big Pharmas to accelerate their research programs, high-tech molecule modeler Schrödinger is taking its first steps as a clinical company. read more By Nick Paul Taylor Astellas has struck its second immuno-oncology deal of the month. The latest pact will see the Japanese drugmaker pay Sutro Biopharma $90 million, plus potentially upward of $1 billion in biobucks, for rights to three immunostimulatory antibody-drug conjugates, a modality designed to combine the best features of ADCs and personalized vaccine biology. read more By Kevin Dunleavy Jazz Pharmaceuticals has revealed a setback, saying that its nabiximols oromucosal spray has flunked a phase 3 trial, coming up short in helping multiple sclerosis patients with lower-limb spasticity. Over a 21-day span, the spray—known as Sativex and on the market in Europe for 12 years—failed to improve muscle tone as measured by the Modified Ashworth Scale (MAS). read more By Conor Hale Bayer is diving into the radiology AI market, which the drugmaker estimates will grow by more than 25% per year between now and 2025. read more By Robert King CMS announced a new payment model aimed at improving care coordination and services for cancer treatments, including a new focus on improving health equity. read more By Gareth Macdonald Clinical trials are generating more data than ever and researchers need systems capable of recording, storing and managing the additional information, says tech firm Medidata. read more |
